Iventi 400 mg/250 ml IV Infusion

Overview

Iventi (Moxifloxacin Hydrochloride) 400 mg/250 ml IV Infusion is a 4th generation broad-spectrum fluoroquinolone antibiotic for intravenous use, manufactured by Square Pharmaceuticals PLC. It inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, essential enzymes for bacterial DNA replication and repair. The IV formulation is indicated for adults (>18 years) with serious bacterial infections requiring parenteral therapy, including acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, complicated skin and skin structure infections, complicated intra-abdominal infections, and pelvic inflammatory disease.

Dosage and Administration

400 mg (one 250 ml bottle) administered by intravenous infusion once daily. Infuse over 60 minutes. Acute bacterial sinusitis: 7–10 days. Acute exacerbation of chronic bronchitis: 5–10 days. Community-acquired pneumonia: 7–14 days. Uncomplicated skin infections: 7 days. Complicated skin infections: 7–21 days. Complicated intra-abdominal infections: 5–14 days. Pelvic inflammatory disease: 14 days. Sequential IV-to-oral therapy with Iventi tablet is possible. No dose adjustment is required for renal or hepatic impairment (except severe hepatic insufficiency — use with caution). Not recommended for patients under 18 years.

Interaction

Avoid concurrent use with QT-prolonging drugs. Antacids, sucralfate, multivalent cation products, and multivitamins may reduce absorption of oral moxifloxacin but are less relevant for IV administration. Concomitant use with NSAIDs increases convulsion risk. Concurrent warfarin use increases bleeding risk — monitor INR closely.

Contraindications

Contraindicated in patients with known hypersensitivity to moxifloxacin or other quinolones. Avoid in patients with known QT interval prolongation, uncorrected hypokalemia, or concurrent Class IA or Class III antiarrhythmic therapy.

Side Effects

Common side effects include nausea, vomiting, diarrhea, headache, and dizziness. Increased risk of tendinitis and tendon rupture — discontinue immediately if tendon pain or swelling occurs. QT prolongation may occur; monitor ECG in at-risk patients.

Pregnancy and Lactation

FDA pregnancy category C. Moxifloxacin is not recommended during pregnancy or lactation.

Precautions and Warnings

Administer by slow IV infusion over 60 minutes only — do not give as rapid bolus injection. Discontinue if signs of tendinitis or tendon rupture occur. Avoid in patients with QT prolongation or hypokalemia. Monitor liver function in patients with hepatic impairment. Not for use in children under 18 years.

Storage Conditions

Store as directed on the packaging, away from light and heat. Keep out of the reach of children. For hospital or clinical use only.

Frequently Asked Questions

Q: When is the IV infusion form of Iventi used instead of the tablet?
A: The IV infusion is used for patients who require parenteral therapy — typically in hospital settings for severe infections or when oral administration is not feasible. Patients may be switched to Iventi 400 mg oral tablet once their condition improves.

Q: How long should the IV infusion take?
A: Each 250 ml bottle of Iventi IV infusion should be administered over 60 minutes. Do not give as a rapid intravenous bolus injection.